This site uses cookies. To find out more about cookies and how to manage them please see our Cookie policy.
By using this website you agree to cookies being placed on your device.

Welcome

The European Medicines Agency (EMA) has granted authorisation for Bronchitol for the treatment of cystic fibrosis (CF) in adults aged 18 years and above as an add-on therapy to best standard of care.1

Bronchitol is an inhaled hyperosmotic therapy, delivered via a simple inhaler.1

The exact mode of action of Bronchitol is unknown, but it is believed to target the underlying pathophysiological airways’ defect in CF to change the viscoelastic properties of mucus, increase the hydration of the periciliary fluid layer, contributing to increased mucus clearance of the retained secretions through mucociliary activity.1

Productive cough can contribute to sputum clearance.1



Ref 1. Bronchitol - Summary of Product Characteristics (see link below)

Adverse events should be reported to Pharmaxis Ltd by email: adverse.events@pharmaxis.com.au.